Morphine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Morphine: From Severe Pain to Myofascial Pain Syndrome
One-Sentence Summary
Morphine is a long-established opioid analgesic (mu-opioid receptor agonist) marketed in the US in many forms. The TxGNN model predicts it may be effective for myofascial pain syndrome, but the retrieved evidence does not test morphine for this condition. None of the 30 registered trials and 16 publications retrieved for this prediction tests morphine for myofascial pain syndrome.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pain management (opioid analgesic; the label indication text was not present in the supplied data) |
| Predicted New Indication | Myofascial pain syndrome |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Morphine is a mu-opioid receptor agonist that produces central analgesia, and its efficacy in severe pain is well established.
The prediction is only weakly plausible. Myofascial pain is mainly peripheral and sensitization-driven, and it is not generally considered opioid-responsive. The high TxGNN score most likely reflects the generic “pain” node neighborhood in the knowledge graph rather than a disease-specific mechanism.
The retrieved trials support this reading. Most are non-drug interventions such as dry needling, massage, rTMS and exercise. Others use opioids only as an outcome measure, for example opioid consumption after knee arthroplasty.
Clinical Trial Evidence
The 10 most relevant of 30 retrieved trials are shown. None tests morphine as treatment for myofascial pain syndrome.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07413770 | N/A | Recruiting | 60 | Classical massage RCT in myofascial pain syndrome; non-drug, does not test morphine |
| NCT04066426 | Phase 4 | Completed | 200 | Naproxen-codeine vs naproxen+dexamethasone vs naproxen for myofascial (TMD) pain; codeine is an opioid, and this is the closest drug comparator |
| NCT06955923 | Phase 2 | Completed | 11 | Trigger point injections after knee arthroplasty to reduce pain and opioid use |
| NCT04640896 | Phase 4 | Recruiting | 60 | Trigger point injections vs traditional therapies for myofascial pain after anterior cervical surgery |
| NCT05478928 | N/A | Unknown | 60 | Invasive physiotherapy techniques (microelectrolysis, dry needling) in myofascial trigger points |
| NCT04684784 | N/A | Completed | 46 | Dry needling and electromyographic activity in latent trigger points |
| NCT03271151 | Phase 4 | Completed | 160 | Duloxetine and opioid use after knee arthroplasty; morphine is only an outcome, and the condition is not myofascial pain |
| NCT06179199 | N/A | Not yet recruiting | 40 | tDCS for pain in sedated ICU patients, aiming to limit morphine side effects |
| NCT04504812 | Phase 3 | Completed | 1937 | Sequenced non-opioid strategy for knee osteoarthritis pain; not myofascial pain |
| NCT00580294 | N/A | Completed | 12 | Pilot of opioid rotation from morphine or oxycodone to oxymorphone; not specific to myofascial pain |
Literature Evidence
The 10 most relevant of 16 retrieved publications are shown.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41664327 | 2026 | RCT | Asian Spine J | Dexmedetomidine plus morphine vs ropivacaine for “myofascial infiltration” in spinal fusion; this is a surgical infiltration technique, not myofascial pain syndrome |
| 35066974 | 2022 | Cohort | Pain Pract | Structured stretching program for myofascial pain and opioid usage in “legacy pain” patients |
| 21419546 | 2011 | Review | J Oral Maxillofac Surg | Long-term opioid use in TMJ dysfunction can be neither supported nor refuted by current evidence |
| 22648287 | 2012 | Clinical study | J Anesth | Cervical facet joint injections in long-standing cervical myofascial pain |
| 39793344 | 2025 | Clinical study | Eur J Obstet Gynecol Reprod Biol | Pudendal nerve block for pain after OnabotulinumtoxinA injection for myofascial pelvic pain |
| 20390305 | 2010 | Longitudinal study | Schmerz | Altered pain thresholds during and after opioid withdrawal in chronic low back pain |
| 16713811 | 2006 | Clinical report | J Oral Maxillofac Surg | TMJ arthrocentesis followed by intra-articular morphine infusion for refractory TMJ pain |
| 17870625 | 2008 | RCT | Eur J Pain | Epidural bupivacaine and morphine vs intercostal cryoanalgesia for post-thoracotomy pain |
| 16967674 | 2006 | Review | J Calif Dent Assoc | Oral medications, infusions and injections in differential diagnosis of orofacial pain |
| 21691691 | 2011 | Descriptive study | Rev Assoc Med Bras | Therapeutic approach in 56 patients with failed back surgery pain syndrome |
US Market Information
The 20 US authorizations are all ANDAs. The supplied data contain no approved-indication text. Five records were retrieved; one is a duplicate, so four distinct authorizations are listed.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA211452 | Morphine Sulfate (Hikma) | Injection | — |
| ANDA215194 | Morphine Sulfate (SpecGx) | Tablet | — |
| ANDA079040 | Morphine sulfate (Actavis) | Extended-release capsule | — |
| ANDA202104 | Morphine Sulfate (Upsher-Smith) | Extended-release capsule | — |
Other forms on the US market include injection, tablet, extended-release capsule, extended-release tablet, solution and suppository.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score is not backed by any trial or publication testing morphine in myofascial pain syndrome. Myofascial pain is not generally regarded as opioid-responsive, and opioid dependence and hyperalgesia risks argue against pursuing it.
The same Evidence Pack shows stronger support for other predictions. Restless legs syndrome (rank 4) reaches L3, with a Cochrane review, a national opioid registry and a 2024 report of intrathecal low-dose morphine. It is marked “Research Question” and would be the better lead candidate.
To proceed, the following is needed:
- Package insert warnings and contraindications (blocking data gap for safety screening)
- Mechanism of action data from DrugBank
- Any controlled study of morphine specifically in myofascial pain syndrome; without one, this prediction should stay on hold
- If the team wants to prioritize restless legs syndrome, a separate evaluation of that indication, with a focus on morphine-specific rather than class-level evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.